Figure 2

Concentration of circulating angiogenic factors measured in the sera of patients during cycle 1 of treatment. (A) VEGF-A, (B) VEGF-C and (C) SDF-1. Increases in these factors were detected after dosing with cediranib, but there was no suggestion of relationship with dose or time to treatment failure.